ABIOMED, Inc. (ABMD) Is At $286.22 Formed Wedge; 3 Bullish Analysts Covering VEREIT, Inc. (VER)

VEREIT, Inc. (NYSE:VER) Logo

Among 7 analysts covering VEREIT Inc (NYSE:VER), 3 have Buy rating, 0 Sell and 4 Hold. Therefore 43% are positive. VEREIT Inc had 7 analyst reports since September 1, 2015 according to SRatingsIntel. DA Davidson initiated the stock with “Neutral” rating in Thursday, September 17 report. The company was upgraded on Friday, August 5 by Capital One. JP Morgan upgraded the shares of VER in report on Friday, November 6 to “Neutral” rating. Mizuho initiated VEREIT, Inc. (NYSE:VER) rating on Friday, October 14. Mizuho has “Neutral” rating and $9.50 target. The stock has “Mkt Outperform” rating by JMP Securities on Monday, January 9. The firm has “Buy” rating given on Tuesday, September 1 by Goldman Sachs. On Monday, December 21 the stock rating was downgraded by CapitalOne to “Equal Weight”. See VEREIT, Inc. (NYSE:VER) latest ratings:

ABIOMED, Inc. (ABMD) formed wedge up with $297.67 target or 4.00% above today’s $286.22 share price. ABIOMED, Inc. (ABMD) has $12.67B valuation. The stock decreased 2.02% or $5.91 during the last trading session, reaching $286.22. About 335,208 shares traded. ABIOMED, Inc. (NASDAQ:ABMD) has risen 128.67% since April 9, 2017 and is uptrending. It has outperformed by 117.12% the S&P500.

Investors sentiment decreased to 1.18 in 2017 Q4. Its down 0.12, from 1.3 in 2017Q3. It fall, as 19 investors sold ABIOMED, Inc. shares while 110 reduced holdings. 55 funds opened positions while 97 raised stakes. 36.44 million shares or 5.39% less from 38.51 million shares in 2017Q3 were reported. Country Tru Bancshares stated it has 111,137 shares or 0.9% of all its holdings. House Ltd, a California-based fund reported 4,000 shares. 306,028 were accumulated by New York State Common Retirement Fund. Waddell & Reed accumulated 0.13% or 305,334 shares. Redwood Invs Limited Liability Corp accumulated 9,514 shares. Schroder Investment Mgmt Grp holds 10,865 shares. 33,144 were accumulated by Comerica National Bank & Trust. 74,400 were reported by Ny State Teachers Retirement Sys. Mitsubishi Ufj Tru & Banking holds 0.1% or 310,010 shares in its portfolio. Parametric Portfolio Assocs Lc holds 0.01% or 49,992 shares. Swiss Bancshares reported 71,300 shares or 0.01% of all its holdings. Rmb Mngmt Limited Liability Com holds 37,338 shares or 0.18% of its portfolio. Invesco Ltd owns 186,449 shares. 5,150 were reported by Yorktown Mngmt & Rech. Proshare Advsr Limited Liability Company has 4,760 shares.

Since February 20, 2018, it had 0 insider purchases, and 1 insider sale for $5.41 million activity. 20,000 shares were sold by Greenfield Andrew J, worth $5.41M.

Analysts await ABIOMED, Inc. (NASDAQ:ABMD) to report earnings on May, 3. They expect $0.64 EPS, up 93.94% or $0.31 from last year’s $0.33 per share. ABMD’s profit will be $28.34M for 111.80 P/E if the $0.64 EPS becomes a reality. After $0.70 actual EPS reported by ABIOMED, Inc. for the previous quarter, Wall Street now forecasts -8.57% negative EPS growth.

Among 14 analysts covering Abiomed (NASDAQ:ABMD), 11 have Buy rating, 0 Sell and 3 Hold. Therefore 79% are positive. Abiomed has $370.0 highest and $80 lowest target. $243.80’s average target is -14.82% below currents $286.22 stock price. Abiomed had 33 analyst reports since August 4, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, February 1 by Jefferies. The stock has “Buy” rating by Jefferies on Thursday, December 21. Jefferies maintained the shares of ABMD in report on Tuesday, June 6 with “Buy” rating. As per Thursday, January 4, the company rating was maintained by Piper Jaffray. Leerink Swann maintained ABIOMED, Inc. (NASDAQ:ABMD) rating on Wednesday, May 4. Leerink Swann has “Outperform” rating and $125 target. BTIG Research maintained the shares of ABMD in report on Tuesday, August 4 with “Hold” rating. On Thursday, April 6 the stock rating was upgraded by PiperJaffray to “Overweight”. The rating was upgraded by Raymond James to “Outperform” on Friday, October 30. Guggenheim maintained ABIOMED, Inc. (NASDAQ:ABMD) on Friday, February 2 with “Buy” rating. Stephens maintained ABIOMED, Inc. (NASDAQ:ABMD) on Friday, February 2 with “Buy” rating.

ABIOMED, Inc. (NASDAQ:ABMD) Institutional Positions Chart